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Abstract  
There is a need for new high throughput drug screening models that are able to reliably 
and efficiently predict drug safety and efficacy during preclinical studies. Transcription 
factor activated reporter gene (TFAR) cassettes can be utilised in vitro and in vivo to 
quantify and define modulation of transcription factor activity in response to 
pharmacological stimulation. Insertion of such genetic constructs into target cells or 
tissues necessitates the use of genetic manipulation technologies and lentiviral vectors 
enable permanent integration of these TFAR constructs into a range of cell types. The 
aim of this project was to create a cell based model for drug screening using a range of 
previously constructed lentiviral TFARs responsive to NFκB, NRF2, TFEB, AP-1, TCF/LEF 
(Wnt Signalling), STAT3 and HIF transcription factors. Human embryonic kidney 
(HEK)293T cells were transduced with a lentiviral TFAR construct. Clonal selection and 
expansion was performed in response to known agonists for each TFAR. The clonal 
TFAR-HEK293T cell line panel was provisionally evaluated for responses to a pro-
inflammatory cytokine (TNF-α), a cytokine-mediated phorbol ester (PMA) and a GSK-3β 
inhibitor (LiCl2). Fully quantitative luciferase luminometry data showed that all three 
factors activated the predicted canonical cell signalling pathways (NFκB, AP-1 and 
TCF/LEF respectively) but also activated non-canonical pathways. Results were broadly 
consistent with current literature, demonstrating that the clonal TFAR transduced cell 
based model could be a valuable first stage platform for evaluating newly synthesised 
drugs or screening drug libraries.  
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1.0 Introduction  
1.1 Drug Screening Models  
The development of preclinical assays with improved target specificity readouts would 
improve intelligent drug design and drug library screening efficiency. There is a critical 
need for new models that are able to reliably predict drug specificity in human cells (Esch 
et al., 2015). In vivo evaluations remain a critical component of preclinical drug safety 
and efficacy and currently remain more applicable to human use than 2D cell based 
models (Szabo et al., 2017). Models may range from simple organisms such as yeast 
(Saccharomyces cerevisiae), to lower vertebrates such as zebrafish (Danio rerio) and 
mammals such as mice (Mus musculus); each having varying degrees of similarity to 
humans and thus provide different benefits. Models that are of higher complexity tend 
to be lower throughput. Zebrafish are a particularly useful model for investigation of 
metabolic regulation and for study of conserved genes associated with human metabolic 
dysfunction, as they conserve function of the liver, pancreas and adipose tissue (Kamel 
and Ninov, 2017). Limitations of drug screening using animal models are that they can 
be costly and tend to be lower throughput than cell based models. It is broadly agreed 
that human cell models are the first line for drug development but traditional models 
lack scalability to high throughput and fidelity in data outputs. 
 
Human Pluripotent Stem cell (hPSC) derived 3D Organoids are an emerging cell-based 
model for drug screening. For example induced pluripotent stem cells (iPSCs) derived 
from patients with neurodevelopmental disorders have been shown to produce 3D 
organoids which display disease phenotype in vitro, demonstrating that hPSC derived 
brain organoids may be useful for neurodevelopmental disease modelling (Lee et al., 
2017). Liver organoids also have significant potential to be used for the investigation of 
the systemic toxicity and liver toxicity which may occur during drug metabolism (Ranga 
et al., 2014). Due to their potential applications in toxicology studies and in investigation 
of drug metabolism within organs such as the liver, 3D organoids have the capacity to 
bridge the translational gap between drug testing in animal models and in human clinical 
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trials. However, organoids are time consuming and costly to produce on the scale 
necessary for drug screening and results may be challenging to reproduce due to 
variation in organoid formation, for example, 3D brain organoids have been noted to 
vary in the size and number of ventricular zone (VZ)-like regions which they develop (Lee 
et al., 2017). This is indeed an exciting area of research and development but the 
widespread application of organoid culture in the drug development field is some way 
off. A further iteration of this technology for drug screening is the ‘organ-on-a-chip’, 
described as a biomimetic system which aims to simulate the complex physiological 
functionality, structure and microenvironment of key human organs (Esch et al., 2015). 
Organ-on-a-chip technology uses microfluidics technologies to control the 
microenvironment of cultured cells. This results in an in vitro cell culture model that is 
able to simulate physiological responses to pharmacological stimulation. This 
technology is also amenable to high throughput drug screening, however is costly to 
produce and currently not scalable.  
 
There are currently remarkably few industry standard cell assays employed for pre-
clinical drug screening; cytochrome p450 assays in the HepG2 liver cell line is one 
example. However, many drugs still present with off-target effects during the clinical 
trials phase, which leads to significant increases in costs and a reduction in progress 
during drug development. Hence, there remains an unmet need for inexpensive, high-
throughput preclinical drug screening models, which are able to better define the 
expansive range of biological modulations that occur on pharmacological stimulation. 
Improved understanding of these biological effects earlier in the process of drug 
development will facilitate selection of drugs more appropriate for further screening, 
and will potentially aid the development of pharmaceuticals with reduced off target 
effects.  
 
1.2 Cell Signalling and Transcription Factors 
Transcription factors (TFs) have a fundamental role in control and regulation of cellular 
processes. They almost always contain a DNA binding domain (DBD) specific to a 
particular region of DNA. Binding to this region causes recruitment of RNA polymerase 
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and initiation of nuclear transcription. TF activation can lead to the expression or 
repression of a multitude of genes with diverse functions. The modulation of 
transcription factors that occurs on pharmacological stimulation is an important 
indicator of the on-target and off-target effects that may present during human clinical 
trials. Cell signalling pathways have been well defined for biological processes implicated 
in disease such as; inflammation, autophagy, cell proliferation, apoptosis, the 
antioxidant response, hypoxia and development. Examples of TFs characteristic of these 
pathways are; NFκB, TFEB, AP-1, STAT3, NRF2, HIF and TCF/LEF (Wnt signalling).  
Measuring TF modulation on pharmacological stimulation enables evaluation of these 
specific biological responses to drug administration. For example, NFκB gene expression 
can be used to determine if a drug is activating the inflammatory response or, 
alternatively, acting as an anti-inflammatory.  
 
1.2.1 Canonical NFκB signalling 
Nuclear factor kappa light chain enhancer of activated B cells (NFκB) refers to a family 
of transcription factors involved in regulation of inflammation, immunity, cellular 
growth, differentiation, apoptosis and tumorigenesis (Ghosh and Dass, 2016), (Nennig 
and Schank 2017). NFκB regulates gene expression in response to pro-inflammatory 
cytokines including TNF-α and Interleukins (IL) -1, 2, 6, 8 and 12. NFκB also acts as an 
activator of transcription for a range of proteins with anti-apoptotic function (IAPs, FLIP, 
Bcl-xL, Bfl-1, survivin) and adhesion molecules (E-selectin, VCAM-1 and ICAM-1) 
(D’Ignazio et al., 2017). NFκB signalling has also been demonstrated to mediate complex 
behaviours including learning and memory, stress responses, anhedonia and drug 
reward (Nennig and Schank, 2017). NFκB family proteins RelA (p65), RelB, c-Rel, NFκB1 
(p105) and NFκB2 (p100) are the principle signalling molecules (Park and Hong, 2016) 
but canonical pro-inflammatory responses are mediated through the p65/p50 
heterodimer. NFκB1 and NFκB2 are synthesised as polypeptides which are later cleaved 
to produce subunits p50 and p52 which are able to bind DNA and initiate transcription 
(Hoesel and Schmid, 2013), other family proteins function to expose activation sites 
during activation and transcription (Ghosh and Dass, 2016). All NFκB subunits contain 
an N-terminal with a Rel Homology domain (RHD), which mediates DNA binding to sites 
in promoters of target genes (Caamaño and Hunter, 2002). NFκB has been identified in 
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almost all cell types and is generally found in the form of a homo/heterodimer complex, 
which is formed from dimerization of Rel-like proteins. NFκB transcriptional response is 
determined by NFκB dimerization, and association of dimers with co-activators, 
repressors and other transcription factors such as STAT3, p53 and HIFs. 
NFκB based regulation of gene expression may occur via canonical, non-canonical or 
atypical pathways. Dysregulation of NFκB canonical and non-canonical pathways has 
been linked with increased risk of malignancies (D’Ignazio et al., 2017), (Hoesel and 
Schmid, 2013). In canonical NFκB signalling, binding of ligands such as Tumour Necrosis 
Factor α (TNF-α), Interleukin-1 (IL-1) or Lipopolysaccharides (LPS) to cell surface 
receptors induces intracellular recruitment of the ‘activation platform’. This consists of 
adaptors and protein kinases and is able to phosphorylate and therefore activate the 
Inhibition of κB Kinase (IKK) complex. On activation, the IKK complex phosphorylates IκB 
inhibitor molecules which hold NFκB inactive in the cytoplasm (D’Ignazio et al., 2017). 
Phosphorylated IκB inhibitor molecules subsequently undergo polyubiquitination and 
proteasomal degradation, thus enabling NFκB nuclear translocation and gene 
transcription (Park and Hong, 2016). 
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Figure 1. Mechanisms for canonical and non-canonical NFκB signalling. Image taken from D’Ignazio et al., 
(2017). 
 
Inflammation is a biological stress response and is associated with activation of 
canonical NFκB signalling (Hoesel and Schmid, 2013). Dysregulated NFκB signalling is 
associated with chronic inflammation and can be seen in disorders such as asthma, 
arthritis and inflammatory bowel disease. Chronic inflammation can also lead to cancer 
development via inhibition of apoptosis and promotion of angiogenesis and cell 
proliferation. NFκB has been shown to both promote and suppress tumour progression, 
depending on the cellular situation (Xia et al., 2014) 
 
1.2.2 NRF2 signalling 
Nuclear factor erythroid 2-related factor 2 (NRF2) is a master regulator of the response 
to oxidative stress (Smith et al., 2016). NRF2 plays an important role in maintaining 
redox homeostasis balance between levels of reactive oxygen species (ROS) inducers 
and ROS scavengers (Gorrini et al., 2013). Controlled production of oxidants is important 
for regulating signalling pathways such as inflammation, immune function, cell division 
and autophagy. However, uncontrolled levels of oxidants result in oxidative stress and 
impaired cellular functions, and may lead to development of chronic disease, toxicity 
and cancer (Ma, 2013). The antioxidant response comes in the form of ROS scavengers, 
which prevent ROS induced damage to cellular organelles. ROS scavengers include 
glutathione (GSH), NADPH, tumour suppressors and dietary antioxidants. NRF2 
upregulates antioxidant-response genes leading to expression of GSH and thioredoxin 
(TXN), both of which are able to reduce ROS and regenerate using NADPH (also 
expressed as a result of NRF2 DNA binding).  
 
Under non-stressful conditions, cytoplasmic NRF2 is bound to kelch-like enoyl-CoA 
hydratase-associated protein 1 (KEAP1), a protein in the cytosol, which is anchored to 
actin in the cytoskeleton. When NRF2 is held in the KEAP1-NRF2 complex, the protein 
ubiquitin is able to bind and cause poly-ubiquitination of NRF2 via cullen3 (Cul3) binding. 
Poly-ubiquitination of NRF2 leads to proteasomal degradation and thus prevents DNA 
transcription (Zhou et al., 2016). Nuclear KEAP1 proteins can also target NRF2 for 
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proteasomal degradation. In the nucleus, NRF2 is constitutively expressed to maintain 
basal expression of antioxidant genes (Smith et al., 2016). Within the KEAP1 protein, 
there are cysteine residues containing thiol groups (R-S-H). Under conditions of 
oxidative stress, ROS and electrophiles reduce the thiol group of KEAP1 to disassociate 
the KEAP1-NRF2 complex. Disassociated NRF2 becomes phosphorylated at Ser40 and is 
translocated to the nucleus to bind with antioxidant response elements (ARE) of 
promoter regions of target genes. ARE binding regulates expression of genes associated 
with cellular response to oxidative stress. After DNA transcription has occurred, 
phosphorylation at Tyr568 causes exportation of NRF2 from the nucleus. Cellular 
oxidants may also cause dissociation of the KEAP1-NRF2 complex by activation of the 
PI3K enzyme and subsequent depolymerisation of the actin cytoskeleton, which holds 
the KEAP1 protein in place (Smith et al., 2016). 
 
Figure 2. Mechanisms for NRF2 degradation and nuclear translocation. Image taken from Sykiotis and 
Bohmann (2010). 
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NRF2-ARE signalling is involved in modulating gene expression of over 500 genes, coding 
for detoxification enzymes, transport proteins, growth factors, receptors and other TF’s. 
(Kim et al., 2017), (Bryan et al., 2013), (Velichkova and Hasson, 2005), (Smith et al., 
2016). Dysregulation of NRF2 expression is associated with increased cellular toxicity 
and over-activation of NRF2 can lead to multi-drug resistant cancer and cardiovascular 
disease.  
 
1.2.3 HIF signalling 
Hypoxia is a pathophysiological condition in which there is diminished oxygen 
availability to cells (Kim and Lee, 2017). In response to low oxygen availability, cells 
upregulate expression of hypoxia Inducible Factors (HIFs), which promote adaptive 
mechanisms to hypoxia. HIFs are a family of basic-helix-loop-helix TFs and each HIF is a 
heterodimeric complex formed by binding of a HIFα subunit to a HIF-1β subunit. Three 
isoforms of HIF-α have thus far been identified, HIF-1α, HIF-2α, and HIF-3α. HIF-1α is 
ubiquitously expressed, HIF-2α expression has been detected in the kidney, endothelial 
cells, heart, lungs and placenta and expression of HIF-3α is thought to occur primarily in 
the kidneys and in lung epithelial cells (D’Ignazio et al., 2017). HIFs mediate DNA 
transcription for cellular adaptions to hypoxia (Jun et al., 2017). In areas of localised 
ischaemia, HIF promotes vascularisation in hypoxic areas via upregulation of processes 
such as angiogenesis. HIF-1β is expressed constitutively and is nuclear (Xiong and Liu, 
2017), (Garziera et al., 2017). HIF-1α is cytoplasmic and its concentration is regulated by 
oxygen. Under normoxic conditions, HIF-1α is hydroxylated on proline residues by a 
prolyl-4-hydroxylase (PHD) enzyme (Garziera et al., 2017). This enables binding with the 
von Hippel-Lindau protein (pVHL), a tumour suppressor protein, which targets HIF-1α 
for polyubiquitination and subsequent degradation by the proteasome. PHDs are 
oxygen dependent, and thus have limited function in hypoxia where lack of 
hydroxylation permits HIF-1α to translocate to the nucleus and form a heterodimeric 
complex with HIF-1β. This complex ‘HIF-1’ binds to hypoxia response elements (HREs) 
and upregulates expression of immune pathways and hypoxia response genes (Garziera 
et al., 2017). 
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Figure 3. Mechanisms for HIF dimerization and gene transcription.  Image taken from Supuran (2017). 
 
HIF-1 binding to its consensus sequence in the promoter of target genes upregulates 
expression of proteins such as; vascular endothelial growth factor (VEGF), glucose 
transporters (GLUT1-3), enzymes CA IX and XII, and erythropoietin 1, which respectively 
mediate cellular mechanisms such as angiogenesis, aerobic glycolysis, pH regulation and 
erythropoiesis (Supuran, 2017).  
HIF-1 is increased in many cancers through upregulation of genes implicated in 
angiogenesis, and re-modelling of the extracellular matrix (ECM), HIF-1 also improves 
cancer cell survival in oxygen depletion conditions via metabolic reprogramming. 
Furthermore HIF signalling can increase secretion of cytokines that are able to suppress 
both adaptive and innate immune responses (Garziera et al., 2017). High levels of HIF-1 
at the tumour site indicate reduced response to chemotherapy and radiotherapy and 
are associated with poor patient prognosis (Supuran, 2017). HIF inhibitors are in various 
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stages of clinical and pre-clinical drug development for treatment of a range of cancer 
types: topoisomerase 1 inhibitors, for example function in part by inhibition of HIF-1α 
expression (Yu et al., 2017), (Kumar and Choi, 2015). Inhibitors of HIF PHD have been 
shown to improve outcome in ischemic and haemorrhagic models of stroke 
(Karuppagounder and Ratan, 2012) and results from Guo et al., (2016) supported 
involvement of HIF-1-VEGF-vascular endothelial growth factor receptor (VEGFR) 
signalling in development of new vessels during recovery after cerebral ischemia. 
Depletion of HIF-1 is also associated with impaired wound healing by preventing normal 
cell signalling responses to hypoxia, whereas HIF hyperactivity can cause excessive 
production and deposition of matrix, leading to fibrosis (Hong et al., 2014). Huang et al., 
(2017) treated skin flaps on mice with hypertonic glucose (sapylin) and found improved 
wound healing correlating with increased VEGF-A and HIF-1α in comparison with the 
control, saline. HIF and its TF targets therefore represent druggable targets in the 
treatment of cancer, ischaemia and wound healing (Jun et al., 2017).  
 
1.2.4 AP-1 signalling 
Activator protein–1 (AP-1) is the name given to dimeric transcription factors comprised 
of Jun, Fos, musculoaponeurotic fibrosarcoma (Maf) or activating transcription factor 
(ATF) family subunits, which bind to a common DNA site (AP-1 binding site) (Tewari et 
al., 2017). AP-1 TFs contain a basic a leucine-zipper (bZIP) consisting of a leucine zipper 
domain and a basic DNA-binding domain. The bZIP domain is required for formation of 
dimers with other bZIP proteins and the DNA binding domain determines the genes 
regulated by that specific protein (Kappelmann et al., 2013). 
 
Dimerization between AP-1 subunits- (members of JUN, FOS, ATF, MAF families) enables 
formation of DNA binding complexes and stimulation of gene transcription for genes 
which contain AP-1 DNA recognition element 5′-TGA(C/G)TCA-3′ (Kappelmann et al., 
2013). When activated, AP-1 can bind with the cMAP response elements (CRE) or the 
12-O-tetradecanoylphorbol-13-acetate (TPA) response element (TRE) to induce gene 
transcription (Gào and Schöttker, 2017). AP-1 gene transcription is associated with 
regulation of cellular proliferation, metabolism, differentiation, oncogenic 
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transformation, apoptosis and cell migration (Tewari et al., 2017) and AP-1 can be 
activated by chemokines, cytokines, growth factors, hormones and environmental 
stress. AP-1 proteins may be activated by Jun-N-terminal kinases (JNKs), which occurs 
via involvement of mitogen activated protein kinase (MAPK) pathways and can be 
mediated by stress.  The three subfamilies of MAPKs are; Jun N-terminal kinases 
(JNK)/stress-activated protein kinases (SAPK), extracellular signal-regulated kinases 
(ERK1/2) and p38 MAPK. MAPK pathways lead to activation and phosphorylation of 
proteins Fos and Jun and AP-1 led tumour progression may occur through 
phosphorylation and activation of MAPKs pathways. Dysregulation of AP-1 is associated 
with progression of inflammatory disorders such as asthma, rheumatoid arthritis, 
psoriasis, transplant rejection and cancer (Tewari et al., 2017). AP-1 and its TF targets 
may therefore be a potential target for prevention or treatment of cancer and 
inflammatory disorders.   
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Figure 4. Mechanisms for AP-1 nuclear translocation and gene transcription. Image taken from 
http://www.isogen-lifescience.com/ap1-293 
 
1.2.5 TCF/LEF (Wnt) Signalling 
During mammalian development Wnt signaling is essential for regulation of cell 
proliferation, cell-fate specification, and asymmetric cell division. In adults, Wnt 
regulates tissue homeostasis and stem cell maintenance (Rapp et al., 2017). There are 
19 Wnt ligands and 10 main Frizzled (FZD) receptors identified in mammals. Two sub-
categories of Wnt signalling are the β-catenin dependent canonical pathway, and the β-
catenin independent non-canonical pathways. The non-canonical pathways are termed 
the planar cell polarity (PCP) and Wnt/Ca2+ pathways. In canonical Wnt signaling, 
absence of Wnt initiates formation of a complex between glycogen synthase kinase 3-
beta (GSK-3β), adenomatous polyposis coli (APC) and axis inhibition protein (AXIN), 
termed the β-catenin destruction complex, which phosphorylates β-catenin at serine 
and threonine sites to tag it for degradation by the proteasome. When Wnt is present 
in the canonical signaling pathway, Wnt ligand binding to a FZD receptor initiates 
formation of a receptor complex composed of FZD, Wnt, Disheveled (DVL), lipoprotein 
receptor–related protein (LRP) and AXIN. Phosphorylation of DVL within the complex 
enables inhibition of GSK-3β, preventing it from phosphorylating beta-catenin and thus 
preventing its degradation. β-catenin therefore accumulates and translocates to the 
nucleus to form a complex with T-cell factor (TCF)/ Lymphoid enhancer-binding factor 
(LEF) transcription factors (Rapp et al., 2017). TCF/LEF gene targets include cyclin and c-
myc (Rapp et al., 2017). 
20 | P a g e  
 
 
Figure 1. Schematic diagram of canonical and non-canonical Wnt (TCF/LEF) signaling pathways taken from 
Rapp et al., (2017 
 
 
1.2.6 TFEB signalling 
Transcription Factor EB (binds E-box sequences) is a master regulator of lysosomal 
biogenesis and autophagy (Medina et al., 2015), which is also involved in regulation of 
energy metabolism. TFEB is part of a family of TFs that positively regulates gene 
expression of a network of genes termed the coordinated lysosomal expression and 
regulation (CLEAR) network. Under normal growth conditions, TFEB in the cytoplasm is 
phosphorylated at ser211 and is associated with 14-3-3 family proteins; this retains TFEB 
in the cytoplasm/cytosol and prevents translocation to the nucleus. MTORC1 is a protein 
kinase complex present on the surface of the lysosome, which positively regulates this 
phosphorylation, and promotes upregulation of cell growth and downregulation of 
autophagy. Conditions such as lysosomal stress and nutrient deprivation lead to 
inhibition of mTORC1 and release of Ca2+ from the calcium channel mucolipin 1 
(MCOLN1) on the lysosomal membrane. Increased cytoplasmic Ca2+ leads to activation 
of calcineurin (Cn), which binds to TFEB and causes de-phosphorylation. De-
phosphorylated TFEB is able to dissociate from the TFEB/14-3-3 complex and translocate 
to the nucleus to form homo/ heterooligomers with other members of the 
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microphthalmia transcription factor (MiTF) family, leading to transcription of autophagic 
and lysosomal genes (Medina et al., 2015).  
 
 
Figure 6. Mechanisms of TFEB de-phosphorylation and translocation to the nucleus. Image taken from 
Medina et al., (2015). 
 
 
1.2.7 STAT3 signalling 
Signal transducer and activator of transcription (STAT) proteins are transcription factors 
and signal transducers that regulate cellular proliferation, cell survival, proliferation, and 
the inflammatory response. STAT proteins include STAT3, STAT1-4, and STAT5A and can 
be modulated by ROS and RNS (Gào and Schöttker, 2017). Activation of STAT3 may occur 
as a result of cytokine-Janus kinase (JAK) signalling. Oxidative stress can cause oxidation 
of STAT and JAK, which inhibits cytokine-JAK-STAT signalling. Conversely, increased 
levels of H2O2 can result in inhibition of tyrosine phosphatases and activation of tyrosine 
kinases and thus activation of cytokine-JAK-STAT signalling pathways (Gào and 
Schöttker, 2017). STAT proteins modulate inflammation and tumorigenesis and may 
promote angiogenesis, proliferation and metastasis of cancer cells. Upregulation of 
STAT3 and STAT5 has been detected in various cancer types. STAT3 activation promotes 
gene expression of interleukin-6 (IL-6) and COX-2 which may be involved in mediation 
of cancer-promoting immunity (Gào and Schöttker, 2017). 
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Figure 7. Activation of JAK-STAT3 signaling in Cancer. Image taken from Yu et al., (2014). 
 
 
1.3 Measuring cell signalling: Reporter gene constructs 
Mechanisms of gene expression may be elucidated through measuring modulations in 
transcription factor (TF) concentration, and may be determined via measurement of 
protein concentration through methods such as western blotting.  These measurements 
require cell lysis meaning that measures can only be taken at a single time point (Dai et 
al., 2014). However mechanistic fluctuations during drug metabolism mean that 
repeated or continuous measures are more relevant to drug function in vivo. Reporter 
gene constructs which produce secreted luciferase enable continuous and quantifiable 
measurements of protein modulation in response to pharmacological stimulation and 
have provided accurate results both in vitro and in vivo.  A reporter gene is a gene 
attached to a regulatory sequence that produces a measurable signal upon modulation 
of gene expression (Ghim et al., 2010). A reporter construct consists of a reporter gene 
whose activation is regulated by a promoter. In mammalian cells, promotor regions 
regulate DNA transcription. They contain functional DNA sequences which interact with 
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regulatory proteins such as TFs and gene specific binding proteins. On binding to a gene 
promoter, TFs can form ‘transcriptional switches’ which control gene expression. 
Promoters may be constitutively active, inducible in response to stimuli or active in a 
specific stage of development or a particular cell type (Xu et al., 2013), they also may be 
endogenous or exogenous. Endogenous promoters commonly utilized in reporter gene 
constructs include cAMP response element (CRE), oestrogen response element and c-
fos. These endogenous promoters however, may be affected by interference from 
intracellular signalling, thus exogenous promoters such as the Gal4 response element 
system in yeast may be used in order to reduce non-specific promoter activation (Liu et 
al., 2009).  
 
Cells engineered with reporter constructs express gene products on activation with 
given stimuli. These products may have measurable enzymatic activity or may fluoresce 
when viewed under a specific wave length. Gene products are either intracellular or 
secreted extracellularly. Intracellular products can be quantified in situ or after cell lysis 
and include firefly luciferase (Luc), aequorin, green fluorescent protein (GFP) and β-
galactosidase (LacZ). Extracellular products secreted into the extracellular medium are 
collected for analysis and include β-lactamase, secreted placental alkaline phosphatase 
(SPAP), and variations of luciferase such as nano-luciferase (NLuc) (Liu et al., 2009). 
Secreted products enable repeated sampling and measurements without altering the 
cellular environment or damaging cells. 
 
Reporter gene constructs are versatile and sensitive and are commonly employed as 
‘biodetectors’ for monitoring cellular signalling pathways and identifying regulatory 
regions involved in transcriptional control of gene expression (Liu et al., 2009). They 
have also been used in promoter deletion analysis as well as high-throughput drug 
screening programmes (Xu et al., 2013). Reporter gene assays may be applied for 
investigation of targets such as TFs, nuclear receptors, G-protein coupled receptors 
(GPCRs), receptor tyrosine kinases and enzymes (Xu et al., 2013). We used a dual 
reporter gene construct developed by Buckley et al., (2015) for investigation of TF 
modulation and for development of a clonal transcription factor activated reporter 
(TFAR) drug screening assay. The reporter construct contained a TF binding motif 
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upstream of a minimal promoter, which upon TF binding, drove gene expression of NLuc 
and GFP. 
 
 
 A.                            B.                  C.                   D.                               E.           F. 
Figure 8. Representation of TFAR Gene Construct. A.) Transcription Factor Binding Motif, B.) Minimal 
Promoter, C.) Gene for production of Flag antibody, D.) Gene for production of nano-luciferase (NLuc), 
E.) Bisotronic Linker Peptide. F.) Gene for expression of Green Fluorescent Protein. 
 
The TF binding site contained serial repeats of known transcription factor consensus 
sequences derived from current literature, some examples of which are displayed in 
Table 1. The amount of GFP and Luciferase produced was proportional to TF binding 
(Buckley et al., 2015). 
Table 1. TFs chosen for investigation, disease models which may be investigated by these, specific 
response elements for TF binding and in vitro agonists used for activation. 
 
NLuc is a 19.1 kDa ATP-independent secreted nano-luciferase derived from Oplophorus 
gracilirostris. It is a highly stable bioluminescent protein able to react with a 
Transcription 
Factor 
Disease Model 
Response Element sequence 
(TF binding Motif) 
In vitro agonist 
NFκB Inflammation/Cancer (GGGACTTTCC) x8 TNF-α 
HIF Ischemia/Cancer (TACGTGCT) x8  CoCl2
/ Low O
2
 
TCF/LEF (Wnt 
signalling) 
Development (AGATCAAAGGGGGTA) x8  LiCl2
 
AP-1 Cancer (TGAGTCAG) x8  PMA 
STAT3 Cancer/Development 
(GTCGACATTTCCCGTAAATCGTC
GA) x4  
IL-6 
 NRF2 Toxicity 
(TCACAGTGACTCAGCAAAATT) 
x8   
H
2
O
2
 
TFEB Autophagy (TCACGTGA) x8 
Serum 
starvation/Torin1 
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coelenterazine analog (furimazine) to produce high intensity luminescence (Boute et al., 
2016). Coelenterazine acts as a substrate for NLuc catalysis in a reaction which results in 
the production of photons of bioluminescent light that can be quantified in a 
luminometer and used as a quantitative measure of gene expression. Vargulin acts as a 
substrate for catalysis of the the Cypridina Luciferin in a separate reaction which also 
produces bioluminescence. GFP is a stable fluorescent protein which can be visualised 
using fluorescent microscopy and used as a qualitative measure of gene expression.  GFP 
and NLuc genes were used within this construct due to their biocompatibility and high 
sensitivity. GFP and NLuc are non-overlapping and may be regulated by the same 
promoter, thus were used to produce dual measurements of TF modulation and gene 
expression. Dual reporter systems which use GFP and luciferase give a more complete 
and accurate idea of molecular signalling (Zhang et al., 2017).  
 
 
 
Figure 9. Representation of TF binding to the reporter construct that results in quantifiable production of 
luminescence. 
 
A lentiviral vector was employed for transduction of the TFAR gene construct into 
HEK293T cells. In comparison with plasmid based transduction, viral vectors broaden 
viral tropism and increase length of expression of the reporter cassette (Zhang et al., 
2017). 
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1.3.1 Lentiviral vectors 
Viral and non-viral vectors may be used to deliver and integrate reporter gene constructs 
within a range of cell types. Buckley et al., (2015) used lentiviral vectors to successfully 
integrate cells with a range of TFAR constructs. 
 
Figure 10. Schematic diagram of the lentiviral vector construct used by Buckley et al., (2015) to integrate TFAR 
cassettes into a range of cell types. The vector contains a firefly luciferase-2A-eGFP reporter construct. 
 
The McKay lab have produced a range of plasmid vector constructs for lentiviral 
integration of TFAR cassettes. These plasmids may be delivered to cells via a second-
generation lentiviral packaging system. As part of this system three plasmid vectors are 
delivered to a host cell; the vector construct, the plasmid for production of VSV-G 
envelope proteins and the packaging plasmid containing essential gag/pol viral genes. 
On successful delivery of all three plasmid vectors to a host producer cell, plasmid DNA 
is used to produce lentivirus. The lentiviral vector produced can be collected and used 
to deliver the TFAR cassette to another cell for genomic integration. 
27 | P a g e  
 
 
Figure 11. Plasmid map of vector construct used for lentiviral integration of the NFκB TFAR. Image 
courtesy of Lorna Fitzpatrick. 
 
Lentiviral vectors are able to transduce both dividing and non-dividing cells, have a 
broad tropism and are SIN vectors. Lentiviruses are of the genera retrovirus. All 
retroviruses contain similar genomic make up consisting of gag, pol and env coding 
regions. Gag and pol code for structural proteins and enzymes involved in viral 
replication. Env codes for viral envelope proteins which enable host specific binding. 
Lentiviruses also contain essential gene expression activators (rev1, tat 1, RRE, rev 2, tat 
2) and genes for factors involved in pathogenesis (vpr, vif, vpu, nef) (Elsner and Bohne, 
2017). Lentiviral vectors may be useful in cellular reprogramming, RNA interference, 
CRISPR-Cas9 based genome editing and gene delivery and integration.  
Many recombinant lentiviral systems are based on the HIV-1 virus. For creation of 
replication defective lentiviral vectors, viral genes required for delivery of transgene are 
identified and unnecessary sequences deleted. Antigens present on the viral surface 
determine viral tropism. HIV-1 envelope proteins may be substituted with different 
envelope glycoproteins during viral production to broaden tropism in a process called 
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pseudotyping. Vesicular stomatitis virus glycoprotein (VSV-G) proteins enable gene 
delivery and genomic integration into a wide range of cell types (Farley et al., 2007). 
Plasmids used for lentiviral generation are replication defective and may contain a 
deletion in the 3'LTR, to produce self-inactivating (SIN) virus that inactivates after 
integration. Lentiviral vectors are efficient for gene delivery as they are genome 
integrating and are able to transduce both dividing and non-dividing cells. Lentiviral 
vector systems may be used may be used in gene delivery of siRNA, CRISPR Cas9 and 
miRNA, for molecular investigation and treatment of diseases such as HIV infection, 
cancer and Parkinson’s.  
First, second and third generation lentiviral packaging systems have been developed for 
intracellular generation of lentiviral vectors. First generation systems are no longer in 
use due to the replication potential of viral products. Second-generation systems deliver 
genes to produce virus via three separate plasmids: a transfer plasmid containing the 
transgene, a packaging plasmid carrying gag and pol genes, and an envelope plasmid 
that delivers genes encoding for viral envelope proteins. Third generation lentiviral 
packaging systems divide genes for virus production between four plasmids to reduce 
viral pathogenicity. Second generation lentiviral systems are safe enough for non-clinical 
use and are able to produce a higher viral titre than third generation lentiviral 
production, thus are often the preferred method for lentiviral production. 
Limitations of lentivectors are that they are randomly integrating and thus raise 
concerns of insertional mutagenesis, abhorrent protein expression and cancer (Elsner 
and Bohne, 2017). Viral coding and non-coding sequences may also lead to production 
of background noise which may interfere with reporter gene expression (Zhang et al., 
2017). Furthermore, lentiviral vectors may be immunogenic and cytotoxic (Ramamoorth 
and Narveka, 2015). Alternative gene delivery vectors may offer a safer, less 
immunogenic option for therapeutic purposes and include non-viral vectors which may 
be lipid, polymer, bacterial or inorganic. Non-viral gene delivery vectors have been 
employed for gene delivery of pDNA, SiRNA, shRNA, miRNA (Jayant et al., 2016). Despite 
the limitations that may present with lentiviral vectorology, lentiviruses have been used 
successfully in vitro and in vivo to stably integrate genetic material including complex 
gene constructs into host cell genomes.  
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2.0 Aims 
The overall objective of this project is to utilise lentiviral vectorology techniques to 
generate HEK293T cell lines transduced with selected TFAR constructs (developed by 
Buckley et al., (2015)). In order to achieve this objective, I will first develop clonal 
HEK293T cell lines with single lentiviral integration of the expression cassette for 
candidate TFARs. I will then measure modulation of selected TFs on pharmacological 
stimulation using known agonists/antagonists and drugs. Finally, I will use these 
measurements to hypothesise cellular response to administration of specific drugs. 
 
3.0 Materials and Methods 
3.1 Materials  
Material  Origin Catalogue 
Number  
Dulbecco’s Modified Eagles Medium 
(DMEM) 
Gibco BE12-614F 
Foetal bovine serum (FBS)  Fisher Scientific UK 11550356 
Dimethyl Sulfoxide DMSO  Fisher Scientific UK BP231-100 
Penicillin/Streptomycin (P/S) antibiotics Lonza DE17-603E 
Plasmocin Invitrogen  ant-mpp 
L-Glutamine Lonza 17-605E 
Human Embryonic Kidney cell line 
(HEK293T) 
ATCC CRL-3216 
Trypsin/EDTA Lonza CC-5012 
Plasmid pCMVR8.74 Addgene  22036 
Plasmid pMD2.G Addgene  12259 
OptiMEM® Gibco™ 31985070 
Polyethylenimine (PEI) Sigma-Aldrich 03880 
Cypridina Luciferin (Vargulin) NanoLight 305 
30 | P a g e  
 
Coelenterazine NanoLight 303 
ELISA 2.0 kit ZeptoMetrix 0801002 
Plasmid Mini Kit QIAGEN 27104 
Table 2. Materials used, origin and catalogue number. 
 
3.2 Methods 
3.2.1 Cell Culture  
The human embryonic kidney cell line HEK293T was cultured in DMEM, supplemented 
with 10% FBS, 100x Penicillin/Streptomycin antibiotics and 4mM L-Glutamine, herein 
after referred to as complete DMEM (cDMEM). Cells were incubated at 37°C and 5% 
CO2.  
 
3.2.2 Large scale production of VLuc expressing lentivirus vector  
2x107 HEK293T cells were seeded in a T175cm2 flask and incubated overnight at 37˚C, 
5% CO2 to reach >90% confluence. Cells were then transfected with a cocktail of 3 
plasmids to produce replication defective lentiviral particles; 17.5μg pMD.G2, a VSV-G 
envelope expressing plasmid; 32.5µg pCMVΔR8.74, a second-generation lentiviral 
packaging plasmid and 50µg of vector construct containing the TFAR cassette. 
pCMVR8.74 was a gift from Didier Trono, as was pMD2.G. Plasmid DNA was complexed 
with 10mM PEI in OptiMEM® medium for 20 minutes. After this time, HEK293T cell 
culture media was removed and replaced by the OptiMEM® containing DNA/PEI 
complexes. Cells were incubated at 37°C and 5% CO2 for 3 hours, after which 
transfection media was replaced with complete DMEM.   
 
After 48 hours, cell supernatant containing budding lentivirus was collected and 
subjected to centrifugation at 5000 rpm/ for 10 minutes (Eppendorf 5804 R). 
Supernatant was removed and filtered using a 0.45µm PVDF filter to remove cellular 
debris. Lentivirus was concentrated by centrifugation in a benchtop centrifuge at 5000 
rpm for 16-20 hours at 4˚C in 50mL Falcon tubes. Supernatant was then completely 
removed by aspiration and 50µL OptiMEM® added to the pellet (50µl OptiMEM® added 
per T175 flask). This was incubated on ice for 1 hour to resuspend the pellet. Primary 
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supernatant was then stored in the fridge overnight and the whole process repeated to 
yield a second harvest of supernatant.  After 72 hours the second supernatant was then 
collected and centrifuged as described. Viral pellets were completely resuspended and 
lentivirus suspensions pooled, aliquoted, and stored for future use at -80 ˚C. 
 
3.2.3 Viral Titration 
Titration of VLuc expressing lentivirus (LNT-VLuc) produced from large scale viral prep 
was carried out as per the HIV-1 p24 antigen ELISA 2.0 kit. To prepare reagents, plate 
wash buffer was diluted 1:10 in distilled water (dH2O) and used to wash the microplate 
wells. A series of 6 standards were prepared from the HIV-1 p24 antigen standard using 
the dilution scheme in table. Standards were not treated with Lysing buffer. 450µl of 
sample was treated with 50µl of Lysing buffer. 
 
Standard 
Number 
Concentration of HIV-1 
p24 (pg/ml) 
HIV-1 p24 antigen 
standard (µl) 
Assay diluent 
(µl) 
1 125.0 50 950 
2 62.5 500 of #1 500 
3 31.3 500 of #2 500 
4 15.6 500 of #3 500 
5 7.8 500 of #4 500 
6 3.9 500 of #5 500 
7 0 0 500 
Table 3. Preparation of HIV-1 p24 antigen standard.  
 
Each well of the microplate was washed (x3) with 350µl of 1X plate wash buffer. The 
microplate was blotted to remove all droplets from the wells. Two strips of the 
microplate were made up with prepared standards. 1 well of the microplate was left 
empty for use as a substrate blank. 200µl of standards 1-6 was pipetted into duplicate 
wells and for standard  number 7 (0pg/ml) into triplicate wells. 
 1 (pg/ml) 2 (pg/ml) 
A 125 125 
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B 62.5 62.5 
C 31.3 31.3 
D 15.6 15.6 
E 7.8 7.8 
F 3.9 3.9 
G 0 0 
H Substrate Blank 0 
Table 4. Representation of two strips of microplate configured with prepared standards. 
 
200 µl of each test sample, (prepared as described in the preparation of reagents 
section), was pipetted into duplicate wells. The microplate was covered with a plate 
sealer and incubated for 1.5 hours at 37°C ± 1°C.  Wells were aspirated and washed (x6) 
taking care not to allow the plate to dry out. 100µl of HIV-1 p24 Detector Antibody was 
pipetted into each well, except the substrate blank. The microplate was then covered 
with a plate sealer and incubated for 1 hour at 37°C ± 1°C. The wells were then aspirated 
and washed (x6). 100 µl of Substrate was then pipetted into all wells and incubated 
uncovered for 30 minutes at room temperature (18°- 25°C). A blue colour developed in 
wells containing the p24 viral antigen. The reaction was stopped by pipetting 100 µl of 
Stop Solution into each well, which resulted in a colour change from blue to yellow. The 
optical density of each well was read at 450nm using the HT Synergy Plate Reader within 
15 minutes of the initial colour change.  
 The optical density of the standards were within given ranges indicating test validity. 
The mean absorbance readings of the test samples were within the linear range of the 
assay and within the standard curve so could be used for accurate quantification of viral 
titre. 
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HIV-1 Antigen Concentration (pg/ml)  Average Optical Density at 450nm 
125 1.974 
62.5 1.049 
31.3 0.596 
15.6 0.345 
7.8 0.217 
3.9 0.155 
0 0.082 
Table 5. Known densities of standard HIV-1 antigen concentrations.  
 
A cut-off value was determined and a HIV-1 p24 ELISA Standard Curve was plotted to 
quantitate levels of HIV-1 p24. Mean absorbance was calculated for each p24 standard 
and test sample.  Using computer graphing software, the concentration of HIV-1 p24 
Antigen Standard (pg/ml) was plotted on the X-axis versus the mean optical densities 
for each standard on the Y-axis. Then the concentration of HIV-1 p24 antigen was 
determined in specimens by interpolation or linear regression analysis from the 
standard curve. Dilutions were corrected for, including the 1.1 dilution made during the 
addition of Lysing Buffer.  
 
3.2.4 Isolation of Plasmid DNA  
DNA extraction was carried using QIAGEN Plasmid Mini Kit. GM work was carried out 
according to appropriated SOPs, COSHH and risk assessments. Stbl3 chemically 
competent E.Coli bacteria were defrosted from glycerol stocks and used for inoculation 
of a starter culture of 5 ml LB broth containing ampicillin (0.1mg/ml) for antibiotic 
selection. The culture was incubated at 37°C for 12–16 hours with vigorous shaking using 
SciQuip Incu-Shake MAXI shaking incubator (approx. 300 rpm). Bacterial cells were 
harvested by centrifugation at >8000 rpm (6800 xg) in a table-top microcentrifuge for 3 
minutes at room temperature (15-25°C). After centrifugation, the bacterial pellet was 
resuspended in 250µl Buffer P1 (with added RNAse A) and transferred to a 1.5 ml 
microcentrifuge tube. DNA lysis occurred on addition of 250 µl of Buffer P2 (mixed by 
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inversion 4–6 times). The lysis reaction was neutralised by addition of 350 µl of Buffer 
N3 (mixed immediately and thoroughly by inversion of the tube). A homogeneous 
colourless suspension indicated effective precipitation of SDS. After lysis and 
neutralisation, bacterial DNA was centrifuged for 10 min at 13,000 rpm (~17,900 x g) in 
a table-top microcentrifuge to form a compact white pellet. Supernatants from the 
previous step were applied to the QIAprep spin column by pipetting to enable DNA 
binding to the spin column. This was then centrifuged for 30–60 s, and flow-through 
discarded. QIAprep spin column was washed with 0.5 ml buffer PB and centrifuged for 
30–60 s; flow-through was discarded (in order to remove trace nuclease activity). The 
QIAprep spin column was then washed with 0.75 ml buffer PE and centrifuged for 30–
60 seconds at maximum speed. Flow-through was discarded and tube centrifuged at full 
speed for an additional 1 min to remove residual wash buffer (Residual ethanol from 
Buffer PE may inhibit subsequent enzymatic reactions). QIAprep column was placed in 
a clean 1.5 ml microcentrifuge tube. For elution of plasmid DNA, 40 µl of water was 
added to the centre of each QIAprep spin column, let stand for 1 min, and centrifuged 
for 1 min. All microfuge centrifugation steps were conducted at maximum speed (13,000 
rpm or ~17,900 x g). 
 
3.2.5 Production of TFAR lentivirus 
HEK293T cells were seeded at a cell density of 0.3x106 cells in a 6-well plate, grown to 
>90% confluence and transfected using a series of plasmids; 0.96μg pMD.G2, a VSV-G 
envelope expressing plasmid; 1.79µg pCMVΔR8.74, a 2nd generation lentiviral 
packaging plasmid and 2.75µg of vector construct. pCMVR8.74. Plasmid DNA was 
complexed with Polyethylenimine (PEI) at 0.1mM (Sigma-Aldrich) in OptiMEM® 
(Gibco™) for 20 minutes. After this time HEK293T cell growth medium was removed and 
replaced by the OptiMEM® containing DNA/PEI complexes. Cells were incubated at 37°C 
and 5% CO2 for 3 hours, after which transfection medium was replaced with complete 
DMEM. Transfected cells were incubated for 48h to produce budding lentivirus, then 
supernatant containing lentivirus was harvested. Second viral supernatant was collected 
at 72 hours.  
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3.2.6 Lentiviral transduction of HEK293T cells 
Lentiviral supernatant was filtered using a 0.45 μm filter and added directly to HEK293T 
cells. Transduction of HEK293Ts was achieved by adding 0.5ml of virus containing 
supernatant directly onto HEK293T cells seeded at 0.3 x 106 per well in 6-well cell culture 
plates. 
 
3.2.7. Activation of heterogeneous population using known agonist. 
Heterogeneous populations of cells transduced with the reporter construct were 
activated with known transcription factor agonists. Fluorescence microscopy was used 
to confirm that cells had been transduced and therefore were integrated with the 
reporter construct. 
 
Transcription 
Factor 
In Vitro Agonist Used for 
Validation 
Concentration Incubation 
Time (Hours) 
NFκB Tumour Necrosis Factor-alpha 
(TNF-α)  
10ng/ml 16 
HIF  Cobalt (II) Chloride (CoCl2) 100µM 16 
TCF/LEF (Wnt 
signalling) 
Lithium Chloride (LiCl2) 50mM 48 
AP-1 Phorbol 12-myristate 13-
acetate (PMA)  
10ng/ml 21 
STAT3 Interleukin-6 (IL-6) 10ng/ml 6-16 
NRF2 Pyocyanin  5µg/ml 16 
TFEB Torin1 15µg/ml Torin1  48 
Serum Starvation N/A 3-6 
Table 6. Table displaying TFs, Agonists used for activation, the concentration and duration of use. 
(Concentrations and durations of agonist addition were determined based on current literature and 
titrations done in the McKay Lab). 
 
3.2.8 Clonal Expansion of transduced cells 
HEK293T cells were transduced with LNT-TFAR at a multiplicity of infection (MOI)<1. 
Subsequently cells were trypsinised, diluted and plated at approximately one cell per 
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well in a 96-well plate. Fluorescence microscopy was used to select clones based on pre-
defined inclusion and exclusion criteria. Selected clones were amplified, and re-plated 
for clonal expansion.  
 
3.2.9 Inclusion/Exclusion Criteria: 
Clones must express basal levels of GFP and luciferase as measured by fluorescent 
microscopy and luciferase luminometry, respectively. Mixed populations were 
excluded.   
 
3.2.10 Agonist induction of clonal HEK293T-TFAR cell lines  
HEK293T-TFAR clonal cell lines expressing basal GFP were expanded and activated with 
a known agonist (See Table 1.) Modulations in gene expression in response to a known 
agonist were measured using both fluorescent microscopy and luciferase luminometry.  
 
Selected HEK293T clones were each split 1:6 and plated at equal cell density into 6 wells 
of a 24-well plate. Cells were amplified to ~70% confluence prior to activation. For each 
HEK293T-TFAR clone 3 wells were treated with a vehicle control and 3 wells were 
treated with known agonist in a 24-well plate (as detailed in Table 1.) After 24-72 h cell 
medium containing agonist was replaced with Complete DMEM. Cells were maintained 
in Complete DMEM for 4 hours, and then cell medium was collected to assay using 
luciferase luminometry. 
 
3.2.11 Cell Based Assay for Candidate Drug Screening using HEK-293T-TFAR  
For all future experiments, the chosen seven HEK293T-TFAR cell lines were plated in 
triplicate in a 24-well plate. One 24-well plate acted as a control for vehicle 
administration, agonist was added to the other identical plate. The activity of each 
transcription factor with and without a drug or agonist was quantified by luciferase assay 
and used to determine which transcription factors were modulated by drug addition. 
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3.2.12 Imaging  
All GFP Images were taken using the Leica Live Cell Imager. All below GFP images are 
displayed with a corresponding Phase Contrast image, taken simultaneously to show 
GFP expression relative to cell number.   
 
3.2.13 Statistical analysis 
Statistical analysis on data from in vitro vector analysis was performed using 
Independent Samples t-tests. All data is expressed as mean values ± SEM of at least 
three independent experiments performed in triplicate. A value of p < 0.05 was 
considered statistically significant. All statistical analyses were performed by SPSS 
(Version 22.0, 2013, IBM Corp., Armonk, NY, USA; SPSS Inc., Chicago, IL, USA). 
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4. Results 
Transcription factor activated gene reporter (TFAR) constructs can be used in vitro and 
in vivo to quantify and define modulation of gene expression in response to 
pharmacological stimulation, and may be used to predict drug safety and efficacy during 
preclinical studies. I sought to generate a panel of TFAR cell lines for application in drug 
evaluation by transducing HEK293T cells with lentiviral vectors containing seven 
different TFAR cassettes. 
 
4.1 Lentiviral-TFAR production 
Transcription factor activated reporter gene (TFAR) constructs were originally generated 
and provided for this project by the McKay Lab (Buckley et al., 2015). TFAR constructs 
were developed with a transcription factor binding motif (TFBM) upstream of a minimal 
promoter, which drives expression of green fluorescent protein (GFP) and luciferase 
(Luc) reporter genes (Figure 9.) TFBM were selected and originally isolated from those 
described and independently validated in the current literature. Serial repeats of these 
known transcription factor consensus sequences were commercially de novo 
synthesised (Aldevron, ND, USA) and cloned into the parental lentiviral vector by Buckley 
et al., (2015) using rapid Gateway® cloning. The TFBM consisted of serial transcription 
factor binding sequences, which varied in length and repeat number depending on the 
transcription factor under investigation. Binding of transcription factor (TF) to the TFBM 
resulted in activation of the promoter region and thus upregulated gene expression of 
Luc and GFP reporter genes in a dose responsive manner (Table 1. and Table 2.). I have 
employed gene expression cassettes containing a secreted variant of luciferase called 
NanoLuc. NanoLuc is a strong flash luciferase variant and contains a protein secretory 
signal so is actively exported from the cell and can be quantitated in conditioned media 
by luciferase luminometry. Expression of GFP enables qualitative measurement of 
activity by fluorescent microscopy. Gene expression of NanoLuc and GFP are controlled 
by the same synthetic promoter enabling multi-modal TF activity evaluations. The 
construct also contains a FLAG antibody that can be used for easy detection of 
transgenic protein.  
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HEK293T cells were co-transduced with a TFAR lentiviral vector and a second lentiviral 
cassette expressing a constitutively active control promoter driving expression of 
secreted vargula vuciferase (VLuc) (Appendix: Figure 37.) VLuc luciferase is the luciferase 
produced by Cypridina hilgendorfii, it catalyses the conversion of vargulin substrate in 
an enzymatic reaction to produce light. This reaction can also be quantified using 
luciferase luminometry and can be measured in the same conditioned media as NLuc as 
neither NLuc nor VLuc show activity catalysing the opposite’s substrate. HEK293T cells 
are a human embryonic kidney cell line widely used in cell biology because they are 
comparatively easy to grown, maintain and transfect with DNA vectors. In this project I 
have used these cells for two purposes: a) to generate lentiviral preps and b) to act as 
TFAR expressing cell lines delivered by lentivirus. In this section HEK293T cells were used 
as lentivirus generating factories. 
 
4.2 Production and Titration of VLuc virus 
Titration of VLuc expressing lentivirus (LNT-VLuc) produced from large scale viral prep 
was carried out as per the HIV-1 p24 antigen ELISA 2.0 kit. During this assay, microplate 
wells were coated with a monoclonal antibody specific for the HIV-1 capsid protein p24. 
During incubation of the sample, p24 antigen is bound to the immobilized antibody. 
Bound antigen is able to react with a human anti-HIV-1 antibody conjugated to 
horseradish peroxidase (HRP). When a substrate is added, reaction of the HRP enzyme 
produces colour. The optical density is proportional to the concentration of HIV-1 p24 
antigen within the sample. The absorbance values of a set of standard dilutions are 
plotted and p24 sample concentration can be determined by interpolation from a point-
to-point plot or from a linear regression analysis of the standard curve.   
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Figure 12. HIV-1 p24 ELISA Standard Curve. Results for the standard curve were based on configured 
standards.  
 
Viral titre was determined by first calculating the value of X using the equation of the 
line derived from the HIV-1 p24 ELISA standard curve (X= 19.551pg/ml). This value was 
multiplied by 100 to account for the number of p24 antigens per viral particle, and then 
multiplied by the dilution factor used (106). Viral titre of LNT-VLuc produced was 1.9 x 
109 viral particles per ml. As VLuc expression is controlled by the constitutively active 
spleen focus forming virus (SFFV) promoter, the concentration of vargulin luciferase in 
cell media could be taken as a measure of cell number. This measure was therefore used 
to normalise results for cell number and all cells were transduced with VLuc virus before 
the experiments described below were carried out. 
 
4.3 Transfection 
HEK293T cells were transfected with a cocktail of three plasmids: pMD.G2, a VSV-G 
envelope expressing plasmid, pCMVΔR8.74, a second generation lentiviral packaging 
plasmid and the vector construct, a plasmid containing the lentiviral construct 
expressing the TFAR (Figure 8). For this project, I focused on seven TFARs: AP-1, HIF, 
STAT3, TCF/LEF, NFκB, TFEB and NRF2. HEK293T cells were transfected and then 
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transfection efficiency assessed after 72 h by fluorescence microscopy detection of GFP. 
Figure 13. shows phase and GFP images demonstrating broad transfection efficiency for 
each TFAR. Broadly, the McKay lab have previously noted that the TFARs tend to express 
irrespective of agonist activation after transient plasmid transfection in HEK293T cells 
and only gain agonist-specific activity once the expression cassette is integrated into the 
host cell genome. Consequently, we are able to assess successful transfection of 
HEK293T cells at ~70-90% efficiency. Previous experience has indicated that these levels 
of transfection yield lentiviral titers in the region of 1x105-6  transduction units (ti)/ml 
supernatant. Interestingly, the intensity of expression of each construct varies (AP-1 is 
very strong, TCF/LEF is less intense) after transient transfection. 
 
Figure 13. HEK293Ts Transfected with plasmids for integration of a range of TFARs. Ai). Phase-contrast 
images of HEK293Ts transfected with plasmid vectors for integration of the AP-1 TFAR construct. 
Aii).Corresponding GFP images. Bi). Phase-contrast images of HEK293Ts transfected with plasmid vectors 
for integration of the HIF TFAR construct. Bii).Corresponding GFP images. C). Phase-contrast images of 
HEK293Ts transfected with plasmid vectors for integration of the STAT3 TFAR construct. Cii). 
Corresponding GFP images. D). Phase-contrast images of HEK293Ts transfected with plasmid vectors for 
integration of the TCF/LEF TFAR construct. Dii.) Corresponding GFP images. E). Phase-contrast images of 
HEK293Ts transfected with plasmid vectors for integration of the NFκB TFAR construct. Eii). 
Corresponding GFP images. Fi). Phase-contrast images of HEK293Ts transfected with plasmid vectors for 
integration of the NRF2 TFAR construct. Fii). Corresponding GFP images. All images were taken at 20X 
magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
  
50μm 
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4.4 Titration of Lentivirus and Transduction 
Lentivirus produced was titred to determine the amount of viral media that was 
required for minimal transduction of reporter construct. Due to the relatively high basal 
expression of NFκB seen in HEK293T cells, NFκB virus was selected for this titration. 
Lentiviral integration of the reporter construct within host cell genome occurred at an 
average transduction efficiency of 30%. Low transduction efficiency was desired to 
prevent the occurrence of multiple viral integrations per cell. Based on the transduction 
efficiency achieved, 0.5ml of viral media was diluted with 0.5ml media not containing 
virus for transduction of all future TFARs. HEK293T cells were transduced with LNT-TFAR 
at a multiplicity of infection (MOI) < 1. On average, it was estimated that each 
transduced cell contained a single viral genome integration. 
 
 
Figure 14. Transduction of HEK293Ts with NFκB virus. Each well of cells were transfected with virus 
diluted in varying ratios of media. Ai.) Phase-contrast images of HEK293Ts transduced with 0.0625ml 
viral media to 0.9375ml media. Aii.) Corresponding GFP images display low levels of lentiviral integration. 
Bi.) Phase-contrast images of HEK293Ts transduced with 0.125 ml virus to 0.875ml media. Bii.) 
Corresponding GFP images display an intermediate level of lentiviral integration. Ci.) Phase-contrast 
images of HEK293Ts transduced with 0.25ml virus to 0.75ml media. Cii.) Corresponding GFP images 
display a greater level of lentiviral integration. Di.) Phase-contrast images of HEK293Ts transduced with 
0.5ml virus to 0.5ml media. Dii.) Corresponding GFP images display greatest levels of lentiviral 
integration. All images were taken at 20X magnification using Leica Live Cell Imaging System. Scale bar 
50μm.  
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4.5 Activation of Heterogeneous Population of TFARs with Known 
Agonists  
After lentiviral transduction of HEK293Ts, the resultant population of heterogeneously 
transduced cells was treated with a known agonist (refer to Table 1.) and imaged using 
fluorescence microscopy (Leica Live Cell Imager). GFP expression indicated lentiviral 
integration of the reporter construct. Transduced cells expressed NLuc and GFP on TF 
binding to the TFAR construct and the resultant activation of the synthetic promoter 
sequence. Expression of reporter genes was assumed to be proportional to the level of 
the nuclear translocation of the transcription factor under investigation. Low 
transduction efficiency was desired to reduce the probability of multiple lentiviral 
integrations. Due to the low rate of viral transduction achieved, variations in GFP 
expression are thought to result from diversity in cell signalling within the population 
rather than from multiple viral integrations.    
 
In order to validate our TFAR lentivirus transduced HEK293T cell lines we chose to use 
agonists that have been previously extensively validated in the literature. In brief these 
were: TNF-α for NFκB (Wu and Zhou, 2010), pyocyanin for NRF2 (Liu et al., 2017). PMA 
for AP-1 (Colin et al., 2011), IL-6 for STAT3 (Attia et al., 2017), CoCl2 for HIF (Zhou et al., 
2017) and serum starvation for TFEB TFAR transduced cell lines (Medina et al., 2015). 
Figures 15-22 show representative images of GFP upregulation in HEK293T-TFAR cells 
treated with the appropriate agonists. 
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Figure 15. Heterogeneous Population of HEK293Ts Transduced with NFκB TFAR Activated by TNF-α.  
Ai.) Phase-contrast images of HEK293Ts transduced with the TFAR for NFκB treated with the vehicle 
control. Aii.) Correlating GFP images for vehicle Control. Bi.) Phase-contrast images of Heterogeneous 
NFκB treated with TNF-α (10ng/ml) for 16 hours. Bii.) Corresponding GFP images for treatment with 
TNF-α. GFP images display activation of the NFκB reporter construct on addition of the known NFκB 
agonist TNF-α, indicating successful genomic integration of the NFκB TFAR. All images were taken at 20X 
magnification using Leica Live Cell Imaging System. Scale bar 50μm.  
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Figure 16. Heterogeneous Population of HEK293Ts Transduced with NRF2 TFAR Activated by Pyocyanin.  
Ai.) Phase-contrast images of HEK293Ts transduced with the TFAR for NRF2 treated with the vehicle 
control. Aii.) Correlating GFP images for vehicle Control. Bi.) Phase-contrast images of Heterogeneous NRF2 
treated with pyocyanin (5μg/ml) for 16 hours. Bii.) Corresponding GFP images for treatment with 
pyocyanin. GFP images display activation of the NRF2 reporter construct on addition of the known NRF2 
agonist pyocyanin, indicating successful genomic integration of the NRF2 TFAR. All images were taken at 
20X magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
 
 
 
Figure 17. Heterogeneous Population of HEK293Ts Transduced with AP-1 TFAR Activated by PMA. 
Ai.) Phase-contrast images of HEK293Ts transduced with the TFAR for AP-1 treated with the vehicle 
control. Aii.) Correlating GFP images for vehicle Control. Bi.) Phase-contrast images of Heterogeneous AP-
1 treated with PMA (10ng/ml) for 21 hours. Bii.) Corresponding GFP images for treatment with PMA. GFP 
images display activation of the AP-1 reporter construct on addition of the known AP-1 agonist PMA, 
indicating successful genomic integration of the AP-1 TFAR.   All images were taken at 20X magnification 
using Leica Live Cell Imaging System. Scale bar 50μm. 
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Figure 18. Heterogeneous Population of HEK293Ts Transduced with TCF/LEF (Wnt signalling) TFAR 
Activated by LiCl. Ai.) Phase-contrast images of HEK293Ts transduced with the TFAR for TCF/LEF  
treated with the vehicle control. Aii.) Correlating GFP images for vehicle Control. Bi.) Phase-contrast 
images of Heterogeneous TCF/LEF treated with LiCl (50nM) for 48 hours. Bii.) Corresponding GFP 
images for treatment with LiCl. GFP images display activation of the TCF/LEF reporter construct on 
addition of the known TCF/LEF agonist LiCl, indicating successful genomic integration of the TCF/LEF 
TFAR.  All images were taken at 20X magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
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Figure 19. Heterogeneous Population of HEK293Ts Transduced with STAT3 TFAR Activated by IL-6. 
Ai.) Phase-contrast images of HEK293Ts transduced with the TFAR for STAT3 treated with the vehicle 
control. Aii.) Correlating GFP images for vehicle Control. Bi.) Phase-contrast images of Heterogeneous 
STAT3 treated with IL-6 (10ng/ml)  for 16 hours. Bii.) Corresponding GFP images for treatment with 
STAT3. GFP images display activation of the STAT3 reporter construct on addition of the known STAT3 
agonist IL-6, indicating successful genomic integration of the STAT3 TFAR.  All images were taken at 20X 
magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
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Figure 20. Heterogeneous Population of HEK293Ts Transduced with HIF TFAR Activated by CoCl2. Ai.) 
Phase-contrast images of HEK293Ts transduced with the TFAR for HIF treated with the vehicle control. 
Aii.) Correlating GFP images for vehicle control. Bi.) Phase-contrast images of HEK293Ts transduced 
with the HIF TFAR treated with CoCl2 (100µM) for 16 hours. Bii.) Corresponding GFP images for 
treatment with CoCl2. GFP images display activation of the HIF reporter construct on addition of the 
known HIF agonist CoCl2, indicating successful genomic integration of the HIF TFAR. All images were 
taken at 20X magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
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Figure 21. Heterogeneous Population of HEK293Ts Transduced with TFEB TFAR Activated by Serum 
Starvation. Ai.) Phase-contrast images of HEK293Ts transduced with the TFAR for TFEB treated with 
the vehicle control. Aii.) Correlating GFP images for vehicle control. Bi.) Phase-contrast images of 
HEK293Ts transduced with the TFEB TFAR treated with serum starvation for 4 hours. Bii.) 
Corresponding GFP images for treatment with serum starvation. GFP images display activation of the 
TFEB reporter construct on addition of the known TFEB agonist serum starvation, indicating successful 
genomic integration of the TFEB TFAR. All images were taken at 10X magnification using Leica Live Cell 
Imaging System. Scale bar 100μm. 
 
 
Figure 22. Heterogeneous TFEB 4 hours with Serum Starvation. All images were taken at 20X 
magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
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4.6 Clonal Expansion of transduced cells  
After validation of lentiviral integration within the heterogeneous populations of 
HEK293T cells they were trypsinised, counted using a hemocytometer, diluted in 
suspension and plated at one cell per well in a 96-well plate. Clonal populations that 
exhibited basal GFP expression (as shown in Figure 23.) were selected and expanded for 
further testing. On average ~30% of the colonies picked expressed GFP, thus it was 
assumed that average transduction efficiency was in the region of 30%. Due to the 
lentiviral transduction efficiency achieved based on previous experiments, it was 
assumed that transduced clones contained a single integration of the reporter construct.  
 
 
Figure 23. Expansion of a single cell plated in well of a 96 well plate during the process of Clonal 
Expansion. Ai). Phase-contrast images of clonal cells transduced with the TFAR for NFκB. Aii.) 
Corresponding GFP images. Bi.) Phase-contrast images of clonal cells transduced with the TFAR for 
TFEB. Bii). Corresponding GFP images. All images were taken at 20X magnification using Leica Live Cell 
Imaging System. Scale bar 50μm. Lentiviral integration is indicated by basal GFP expression. 
 
4.7 Clonal Selection: Activation of Clonal Population of TFARs with Known 
Agonists 
Clonal HEK293T cell lines transduced with a selected Lenti-TFAR (HIF, AP-1, TCF/LEF, 
STAT3, NRF2, NFκB and TFEB) that expressed basal levels of GFP were expanded initially 
in the 96-well format. They were then trypsin passaged at a dilution of 1:6 and plated at 
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equal densities into a 24 well plate. Selected clones were then activated using known in 
vitro agonists as previously described in table 1. GFP images were taken for qualitative 
measures of gene expression using fluorescent microscopy and then conditioned cell 
media was harvested for analysis by luciferase luminometry. For each HEK293T-TFAR 
clone, there were three biological repeats for each TFAR; three wells treated with 
vehicle control, and three wells treated with a known agonist. For each well three 
technical repeat luminometry readings were taken. The HEK293T-TFAR clones that 
displayed the greatest increase in activation compared to baseline were selected and 
amplified for further experiments.  
 
 
Figure 24. Representation of plate format during clonal selection.  
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Figure 25. Clonal Population of HEK293Ts Transduced with HIF TFAR Activated by CoCl2. A). Graph 
displaying activation of clonal populations integrated with the TFAR for HIF with the known agonist CoCl2. 
On activation, clone B5 displayed a significant increase (p=0.007) in NanoLuc expression compared with 
the control. Clone B7 also displayed a significant increase in luciferase expression in response to the 
agonist (p=0.011). Clone B5 was most responsive to agonist thus was selected for further testing. Fold 
change results were attained using Luciferase Luminometry data. For all p-values: p*<0.05, p**<0.01 and 
p***<0.001. Bi.) Phase-contrast images displaying selected HIF transduced clone B5 treated with the 
vehicle control. Bii). Corresponding GFP images. Ci.) Phase-contrast images displaying selected HIF 
transduced clone B5 treated with (100µM) the known agonist CoCl2 for 16 hours. Cii.) Corresponding GFP 
images. All images were taken at 20X magnification using Leica Live Cell Imaging System. Scale bar 50μm.  
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Figure 26. Clonal Population of HEK293Ts Transduced with AP-1 TFAR Activated by PMA. A). Graph 
displaying activation of clonal populations integrated with the TFAR for AP-1 with the known agonist 
PMA. On activation, clone F4 displayed the most significant increase (p=0.0129) in luciferase expression 
relative to its control. Clone G4 (p=0.0434). Clone F4 was selected for further testing. Fold change results 
were attained using Luciferase Luminometry data. For all p-values: p*<0.05, p**<0.01 and p***<0.001. 
Bi.) Phase-contrast images displaying selected AP-1 transduced clone F4 treated with the vehicle control. 
Bii). Corresponding GFP images. Ci.) Phase-contrast images displaying selected AP-1 transduced clone 
F4 treated with (10ng/ml) PMA for 24 hours. Cii.) Corresponding GFP images. All images were taken at 
20X magnification using Leica Live Cell Imaging System. Scale bar 50μm.  
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Figure 27. Clonal Population of HEK293Ts Transduced with TCF/LEF (Wnt signalling) TFAR Activated 
by LiCl2. A.) Graph displaying activation of clonal populations integrated with the TFAR for TCF/LEF with 
the known agonist LiCl2. On activation, clone C5 was significantly upregulated by LiCl2 addition 
(p=0.018), but clone D12 displayed the most significant increase (p=0.015) in luciferase expression 
relative to its control. Clone D12 was therefore selected for further testing. Fold change results were 
attained using Luciferase Luminometry data. For all p-values: p*<0.05, p**<0.01, and p***<0.001. Bi.) 
Phase-contrast images displaying selected TCF/LEF TFAR transduced clone D12 treated with the vehicle 
control. Bii). Corresponding GFP images. Ci.) Phase-contrast images displaying selected TCF/LEF TFAR 
transduced clone D12 treated with 50mM LiCl2 for 48 hours. Cii.) Corresponding GFP images. All images 
were taken at 20X magnification using Leica Live Cell Imaging System. Scale bar 50μm.  
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Figure 28. Clonal Population of HEK293Ts Transduced with STAT3 TFAR Activated by IL-6. A). Graph 
displaying activation of clonal populations integrated with the TFAR for STAT3 with the known agonist 
IL-6. On activation, clone A2 displayed the most significant increase (p<0.001) in luciferase expression 
relative to its control. However, Clone A2 didn’t display any visible basal GFP expression, nor did it 
display an increase in GFP expression on activation. Increased GFP expression in response to an agonist 
is a required characteristic for all of the clones in the TFAR based cell screening model. Luciferase 
expression of Clone C7i was significantly increased (p=0.024) on activation with IL-6 and this clone 
displayed a visible increase in GFP. Therefore Clone C7i was selected. Fold change results were attained 
using Luciferase Luminometry data. For all p-values: p*<0.05, p**<0.01, and p***<0.001. Bi.) Phase-
contrast images displaying selected STAT3 TFAR transduced clone C7i treated with the vehicle control. 
Bii). Corresponding GFP images. Ci.) Phase-contrast images displaying selected STAT3 TFAR transduced 
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clone C7i treated with 10ng/ml IL-6 for 16 hours. Cii.) Corresponding GFP images. All images were taken 
at 20X magnification using Leica Live Cell Imaging System. Scale bar 50μm.  
 
 
 
Figure 29. Clonal Population of HEK293Ts Transduced with NRF2 TFAR Activated by pyocyanin. A). 
Graph displaying activation of clonal populations integrated with the TFAR for NRF2 with the known 
agonist pyocyanin. On activation, clone A9 displayed the greatest increase in luciferase expression 
relative to its control. The difference was not significant, however GFP images displayed clear activation 
of this clone on addition of pyocyanin, so clone A9 was selected. Fold change results were attained 
using Luciferase Luminometry data. For all p-values: p*<0.05, p**<0.01, and p***<0.001. Bi.) Phase-
contrast images displaying selected NRF2 TFAR transduced clone A9 treated with the vehicle control. 
Bii). Corresponding GFP images. Ci.) Phase-contrast images displaying selected NRF2 TFAR transduced 
A 
57 | P a g e  
 
clone A9 treated with 5μg/ml pyocyanin for 24 hours. Cii.) Corresponding GFP images. All images were 
taken at 20X magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
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Figure 30. Clonal Population of HEK293Ts Transduced with NFκB TFAR Activated with TNF-α. A). 
Graph displaying activation of clonal populations integrated with the TFAR for NFκB with the known 
agonist TNF-α. Clonal populations integrated with the TFAR for NFκB were activated with the known 
agonist TNF-α. On activation, clone C8 displayed the most significant increase in luciferase expression 
relative to its control (p<0.001). However, GFP expression data did not correlate, so this clone was 
excluded. Clone G2 displayed significant increase in luciferase on addition of TNF-α (p=0.006) along 
with increased GFP expression. Therefore clone G2 was selected. Fold change results were attained 
using Luciferase Luminometry data. For all p-values: p*<0.05, p**<0.01, and p***<0.001. Bi.) Phase-
contrast images displaying selected NFκB TFAR transduced clone G2 treated with the vehicle control. 
Bii). Corresponding GFP images. Ci.) Phase-contrast images displaying selected NFκB TFAR transduced 
clone G2 treated with 10ng/ml TNF-α for 16 hours. Cii.) Corresponding GFP images. All images were 
taken at 20X magnification using Leica Live Cell Imaging System. Scale bar 50μm.  
 
 
 
Figure 31. Clonal Population of HEK293Ts Transduced with TFEB TFAR Activated by Torin1. Ai.) Phase-
contrast images displaying selected TFEB TFAR transduced clone G6 treated with the vehicle control. 
Aii). Corresponding GFP images. Bi.) Phase-contrast images displaying selected TFEB TFAR transduced 
clone G6 treated with Torin1 for 24 hours. Bii.) Corresponding GFP images. On activation, clone G6 
displayed the greatest increase in GFP relative to its control. All images were taken at 20X magnification 
using Leica Live Cell Imaging System. Scale bar 50μm. 
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4.8 Model for drug screening 
The clonal TFAR-HEK293T cell line panel was provisionally evaluated for responses to a 
pro-inflammatory cytokine (TNF-α), a cytokine-mediated phorbol ester (PMA) that acts 
as a PKC activator and a GSK-3β inhibitor (LiCl2). HEK293Ts containing TFAR were plated 
in triplicate in a 24-well plate. One 24-well plate acted as a control and to the other 
plate, agonist was added. TF expression in response to pharmacological stimulation was 
quantified by luciferase luminometry and used to investigate TF modulation (Figure 28). 
 
 
Figure 32. Representative formatting of the clonal TFAR integrated cell based drug screening model.  
 
The clonal TFAR-HEK293T cell line panel was treated with 10ng/ml TNF-α for 16 hours 
for validation of the model. The clonal line transduced with the NFκB TFAR was used as 
a positive control. Results displayed in Figure 33. Indicate that TNF-α significantly 
upregulated gene expression of NFκB (p=0.006), STAT3, TCF/LEF (Wnt signalling) 
(p=0.039), NRF2 (p=0.002), TFEB (0.019), AP-1 (p<0.001) and HIF (0.037).  
 
The clonal TFAR-HEK293T cell line panel was also used to investigate molecular response 
to pharmacological stimulation with known compounds. The panel was treated with 
10ng/ml phorbol 12-myristate 13-acetate (PMA) for 16 hours. The clonal line transduced 
with the AP-1 TFAR was used as a positive control. Results displayed in Figure 34. 
indicate that PMA significantly upregulated gene expression of AP-1 (p=0.003), STAT3 
(p=0.025), HIF (p=0.05), NFκB (p=0.004) and NRF2 (0.005).  
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The panel was then treated with 50mM Lithium Chloride (LiCl2) for 3 days. The clonal 
line transduced with the TCF/LEF (Wnt signalling) TFAR was used as a positive control. 
Results displayed in Figure 35 indicate that LiCl2 significantly upregulated gene 
expression of TFC/LEF (Wnt signalling) (p=0.034), TFEB (p=0.016), AP-1 (p=0.006) and 
STAT3 (p=0.024). LiCl2 significantly downregulated HIF gene expression (p=0.003).  
Changes in gene expression were quantified using luciferase luminometry and 
fluorescence microscopy. All results were normalised using VLuc and expressed as a fold 
change in activation from their individual control. Supporting GFP images are displayed 
in Appendix: (Figures 39-59). 
 
Fully quantitative luciferase luminometry data showed that all three factors activated 
the predicted canonical cell signalling pathways (NFκB, AP-1 and TCF/LEF (Wnt 
signalling) respectively) but also activated non-canonical pathways. Results were 
broadly consistent with current literature, demonstrating that the clonal TFAR 
transduced cell based model could be a valuable first stage platform for evaluating 
newly synthesised drugs or screening drug libraries. The TFAR integrated cell based 
drug-screening model was further validated to test known agonists for off target effects.  
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Figure 33. Validation of Cell Screening Model with TNF-α. Clonal HEK293Ts integrated with the TFAR 
for NFκB, STAT3, TCF/LEF (Wnt signalling), NRF2, TFEB, AP-1, HIF were treated with TNF-α. On activation 
with TNF-α, expression of NFκB was significantly increased (p=0.006), as was TCF/LEF (Wnt signalling) 
(p=0.039), NRF2 (p=0.002), TFEB (0.019), AP-1 (p<0.001) and HIF (0.037). STAT3 was also upregulated 
on addition of TNF-α. Fold change results were produced using Luciferase Luminometry data. For all p-
values: p*<0.05, p**<0.01, and p***<0.001. 
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Figure 34. Addition of LiCl2 for investigation of off-target effects. Clonal HEK293Ts integrated with the 
TFAR for NFκB, STAT3, TCF/LEF (Wnt signalling), NRF2, TFEB, AP-1, HIF were treated with LiCl2. The 
positive control, TCF/LEF (Wnt signalling) was significantly upregulated by addition of LiCl2 (p=0.034). 
Clonal NFκB was upregulated by LiCl2 addition, but results were not significant. Clonal TFEB was 
upregulated by LiCl2 (p=0.016) as were clonal AP-1 (p=0.006) and STAT3 (p=0.024). Clonal HIF displayed 
significant downregulation of gene expression on addition of LiCl2 (p=0.003).  For all p-values: p*<0.05, 
p**<0.01, and p***<0.001. 
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Figure 35. Addition of PMA for investigation of off-target effects. Clonal HEK293Ts integrated with the 
TFAR for NFκB, STAT3, TCF/LEF (Wnt signalling), NRF2, TFEB, AP-1, HIF were treated with PMA. The 
positive control AP-1 was significantly upregulated by PMA (p=0.003), as were STAT3 (p=0.025), HIF 
(p=0.05), NFκB (p=0.004) and NRF2 (0.005). For all p-values: p*<0.05, p**<0.01, and p***<0.001. 
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5.0 Discussion 
The aim of this project was to utilise lentiviral vectorology techniques to generate a 
clonal TFAR-HEK293T cell line panel model amenable to applications such as drug 
screening.  TFAR constructs were generated and provided by the McKay Lab (Buckley et 
al., 2015). These constructs contained a TFBM upstream of a minimal promoter (Figure 
9.) TF binding to the specific TFBM initiated gene expression of associated NLuc and GFP 
genes in a dose responsive manner (Table 1. and Table 2.). HEK293T cells were co-
transduced with the TFAR constructs and a lentiviral cassette consisting of a 
constitutively active promoter driving expression of secreted VLuc (Appendix: Figure 
37.) Transduction was achieved using low concentrations of lentiviral vector for single 
lentiviral integration of each construct within target HEK293T cells. The panel was 
validated using known TF agonists for activation of each TFAR. NLuc measurements were 
taken from conditioned media and used to determine gene response to pharmacological 
stimulation. Results were normalised using VLuc values which were taken from the same 
conditioned media. Results were all displayed as a fold change from their individual 
control. The panel was then provisionally used to detect and measure off-target drug 
effects.  
 
My results indicate successful development of a robust first line TFAR cell screening 
model which is fully quantified and able to produce significant results that are broadly 
consistent with current literature. The cell-screening model consists of clonal cell lines 
transduced with TFAR gene constructs for AP-1, NRF2, NFκB, HIF, STAT3, TCF/LEF (Wnt 
signalling) and TFEB.  
 
TNF-α is a proinflammatory cytokine (Umare et al., 2014). Many of the TFs investigated 
in the TFAR cell-screening model are known to be modulated during inflammation, (Ren 
and Hu., 2017), (Vion et al., 2017), (Shanmugam et al., 2016), (Lin et al., 2016), (Sharma 
et al., 2017), (Miscia et al., 2002), TNF-α was therefore selected to validate the model. 
TNF-α is a well-defined NFκB agonist (Wu and Zhou, 2010) that binds to cell surface 
receptors to induce canonical NFκB signalling, NFκB was therefore used as the positive 
control for this experiment. Results showed TNF-α significantly increased activation of 
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the NFκB TFAR (p=0.006) as expected. TNF-α also significantly (p=0.039) upregulated 
Wnt signalling pathways (TCF/LEF TF activation). The Wnt/β-catenin pathway is involved 
in regulating inflammation in various diseases and there exists a crosstalk between NFκB 
and Wnt signalling pathways during inflammation. Sharma et al., (2017) used the small 
molecule iCRT3 to inhibit Wnt signalling by binding to β-catenin. This blocked 
interactions between β-catenin and TCF and led to a reduction in TNF-α concentration. 
Ma and Hottiger, (2016) proposed that in tumour cells, macrophages release TNF-α 
which is able to activate β-catenin through GSK-3β and Akt signalling and promote 
tumour cell proliferation. NRF2 was shown to be significantly upregulated (p=0.002) in 
HEK293Ts after addition of TNF-α. Shanmugam et al., (2016) described the complex 
interactions between NRF2 and TNF-α signalling, reporting that lower concentrations of 
TNF-α (2-5ng/ml) induced NRF2 nuclear translocation, increased DNA binding and 
transactivation of TF targets. However, increasing TNF-α concentration above 10ng/ml 
resulted in suppression of KEAP1/NRF2 signalling. This indicates concentration 
dependency in NRF2-TNF-α signalling.  
 
 
Figure 36. Schematic diagram showing potential NRF2 activation pathways in response to TNF-α 
(Shanmugam et al., 2016). 
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Addition of TNF-α to HEK293Ts was shown to significantly upregulate cellular expression 
of the transcription factor TFEB (p=0.019). TNF-α induced TFEB activation is supported 
by Vion et al., (2017) who reported that in the endothelium, a deficiency in autophagy 
promotes TNF-α induced inflammation. Brady et al., (2017) described the autophagy-
lysosome pathway as a key player in regulation of the inflammatory response and 
Uchida et al., (2014) reported that in RC4 cells, expression of autophagy-related proteins 
was upregulated in the cornea after treatment with TNF-α. Treatment of HEK293Ts with 
TNF-α was shown to significantly upregulate expression of AP-1 (p<0.001). This result is 
supported by Westwick et al., (1994) who determined that TNF-α prolonged activation 
of the c-jun kinase. Lin et al., (2016) also described that c-jun N-terminal kinases (JNKs), 
extracellular signal-related kinases (ERKs) and p38s may be activated on stimulation with 
TNF-α via MAPK stimulation of AP-1. Gene expression of the HIF TF was significantly 
increased (p=0.037) on stimulation with TNF-α. TNF-α induced HIF-1 activation is 
supported by Ren and Hu., (2017) who found that chronic intermittent hypoxia (CIH) is 
positively associated with TNF-α, indicating that HIF-1α is upregulated by TNF-α. STAT3 
gene expression was not significantly modulated by addition of TNF-α. Miscia et al., 
(2002) reported that TNF-α activates Jak1/Stat3-Stat5B signaling through TNFR-1 in 
human B cells.  
 
The clonal TFAR cell screening model was also used to investigate the off-target effects 
which may be produced on addition of a known pharmacological compound, for these 
experiments, the compounds used were Phorbol 12-myristate 13-acetate (PMA), a PKC 
activator and Lithium Chloride (LiCl2), a GSK-3β specific kinase inhibitor. PMA and LiCl2 
are known agonists of AP-1 and Wnt signalling respectively, and were selected based on 
current literature due to their association with a vast range of cell signalling pathways. 
As AP-1 is known to be activated by PMA, it was used as a positive control (Colin et al., 
2011).  Clonal HEK293T cells transduced with the AP-1 TFAR were activated with 
10ng/ml PMA for 21 hours and displayed a statistically significant (P=0.003) increase in 
activation. Colin et al., (2011) examined the intragenic region of HIV-1 for binding sites 
for TFs which can be induced by PMA (these included NF-κB, AP-1, AP-2 and AP-4). Clonal 
HEK293T cells transduced with the NRF2 TFAR were activated with 10ng/ml PMA for 21 
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hours and displayed a statistically significant (P=0.005) increase in activation. PMA 
induced NRF2 activation is supported by Zhang et al., (2013), who reported increased 
NRF2 phosphorylation and ARE transcriptional activity on addition of PMA to HepG2 
cells. Clonal HEK293T cells transduced with the NFκB TFAR were activated with 10ng/ml 
PMA for 21 hours and displayed a statistically significant (P=0.004) increase in activation. 
PMA induced NFκB activation is supported by Debelec-Butuner et al., (2012) who 
reported a significant increase in levels of TNF-α on addition of PMA in U937 cells. 
Increased TNF-α leads to increased NFκB nuclear translocation (Wang et al., 2013). 
Clonal HEK293 cells transduced with the HIF TFAR were activated with 10ng/ml PMA for 
21 hours and displayed a statistically significant (P=0.050) increase in activation. PMA 
induced HIF activation is supported by Jung et al., (2003) who noted that PMA induced 
increased expression of HIF-1α in normoxic cells. Clonal HEK293 cells transduced with 
the STAT3 TFAR were activated with 10ng/ml PMA for 21 hours and displayed a 
statistically significant (P=0.025) increase in activation. PMA induced STAT3 activation is 
supported by Kwon et al., (2013) who reported PMA induced upregulation of STAT3 
mRNA. Clonal HEK293 cells transduced with the TCF/LEF (Wnt signalling) TFAR were 
activated with 10ng/ml PMA for 21 hours and displayed an increase in activation. Seo et 
al., (2016) described increased phosphorylation and thus inactivation of GSK3β on 
addition of PMA. Inhibition of GSK3β leads to increased Wnt signalling. Clonal HEK293 
cells transduced with the TFEB TFAR were activated with 10ng/ml PMA for 21 hours and 
displayed downregulated protein expression on addition of PMA. Seo et al., 2016 
described PMA as an activator of PKC. Li et al., (2015) describes that activation of PKC 
causes inactivation of GSK3β, which reduces phosphorylation, nuclear translocation and 
activation of TFEB, this indicates that PMA is expected to downregulate expression of 
TFEB, which correlates with the data achieved. 
 
Wnt signalling pathways are known to be activated by LiCl2, so the TFAR for TCF/LEF 
(Wnt signalling) was used as a positive control. Clonal HEK293 cells transduced with the 
TCF/LEF TFAR were activated with 50mM LiCl2 for 3 days and displayed a statistically 
significant (p=0.034) increase in activation. This is supported by Galli et al., (2013) who 
reported that LiCl2 treatment induced TCF/LEF activation and expression of Wnt 
signalling markers in C2C12 cells on modSLA. Furthermore, Xia et al., (2017) reported 
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increased Wnt/β-catenin signalling on addition of LiCl2, which was activated through 
inhibition of GSK3β in the auditory cortex. Clonal HEK293 cells transduced with the NRF2 
TFAR were activated with 50mM LiCl2 for 3 days and displayed a statistically significant 
(p=0.033) increase in activation. Chen et al., (2016) used LiCl2 to inhibit GSK-3β in 
vitro and in vivo and described increased expression of nuclear and total NRF2, of NRF2-
ARE binding activity and of NRF2/ARE pathway-driven gene expression. Chen et al., 
(2016) also showed that overexpression of GSK-3β decreases NRF2 expression and the 
NRF2/ARE pathway in cerebral ischemia. Clonal HEK293 cells transduced with the AP-1 
TFAR were activated with 50mM LiCl2 for 3 days, and displayed a significant increase in 
activation (p=0.006). This is supported by Kwon et al., (2008) who reported that LiCl2 
induced expression of Fra-2 and c-Fos in the amygdala. Clonal HEK293 cells transduced 
with the STAT3 TFAR were activated with 50mM LiCl2 for 3 days and displayed a 
significant (p=0.024) increase in activation. Interactions between LiCl2 and STAT3 
differed in literature: Lim et al., (2008) described that knock down of GSK3-β reduced 
activation of STAT3. LiCl2 is a GSK3-β inhibitor and may reduce activation of STAT3. 
However, LiCl2 upregulates Wnt/beta-catenin pathways which are interlinked with 
STAT3 signalling.  Beurel and Jope., (2009) and Hao et al., (2006) reported that Wnt3a 
upregulated STAT3 activation and nuclear translocation and that reducing STAT3 levels 
with siRNA eliminated Wnt3a related development and protection from oxidative stress. 
Clonal HEK293 cells transduced with the NFκB TFAR were activated with 50mM LiCl2 for 
3 days and displayed a significant (p=0.018) increase in activation. NFκB activation by 
LiCl2 is supported by Chang et al., (2013) who reported that inhibiting GSK-3β 
downregulated activation of NFκB and thus production of TNF-α in GAS-Infected RAW 
264.7 Cells.  LiCl2 is an inhibitor of GSK-3β. Clonal HEK293 cells transduced with the HIF 
TFAR were activated with 50mM LiCl2 for 3 days and displayed significant 
downregulation of HIF gene activation (p=0.003). GSK-3β has been shown to inhibit 
activation of HIF-1α transcription in hepatoma cells (Zhou et al., 2012). Ko et al., (2013) 
reported that inactivation of GSK-3β by hypoxia in gastric cancer cells contributes to 
accumulation of HIF-1α at translational but not transcriptional or post-translational 
levels. HIF and GSK-3β signalling may therefore be cell-type dependant (Ko et al., 2013). 
Clonal HEK293 cells transduced with the TFEB TFAR were activated with 50mM LiCl2 for 
3 days. TFEB was significantly upregulated (p=0.016) by LiCl2 as shown by the results 
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from Luciferase Luminometry. LiCl2 activation of TFEB is supported by Parr et al., (2012) 
who described that in N2a cells, inhibition of GSK-3β led to upregulation of TFEB nuclear 
translocation and autophagy. 
 
The clonal TFAR-HEK293T cell line panel model is amenable to high throughput drug 
testing, is low cost to develop and use and produces reproducible results as it employs 
clonal cell lines. It also enables rapid identification of molecular pathways modulated 
and can improve understanding of interactions between molecular pathways. It 
therefore is advantageous as a drug screening model. The clonal TFAR model also 
displays advantages above other methods of measuring cell signalling and other 
reporter constructs as it uses secreted NLuc which can be collected at multiple time 
points and measured using conditioned media, thus enabling repeated measurements. 
NLuc is also smaller than other luciferases such as Luc and has a brighter luminescence 
intensity. On activation, the clonal TFAR-HEK293T cell line panel model also produces 
GFP to give two non-overlapping dual measures of gene expression. Limitations of the 
clonal TFAR-HEK293T cell line panel model are primarily related to the lentiviral vector 
used to deliver the TFAR gene construct to host cells, as lentiviruses are randomly 
integrating and immunogenic. Random integration of the TFAR construct has the 
potential to result in abhorrent protein expression and cancer. Furthermore, the exact 
number of viral integrations within each clonal cell line is unknown.  
6.0 Future Work 
To resolve concerns over TFAR integration sites within HEK293T cells, the genome of 
each clonal cell line will be sequenced and the site of TFAR insertion determined. This 
will clarify that insertions are within a section of the genome that doesn’t lead to cancer-
causing effects and will also enable determination of the number of viral integrations 
within each cell line. The clonal TFAR-HEK293T cell line panel model will also be used in 
collaboration with Dr. Ahad Rahim, UCL School of Pharmacy for screening of a candidate 
suitable for drug repurposing. Exendin-4 (Ex-4) is a short peptide GLP-1 analogue used 
in treatment of diabetes for upregulation of insulin secretion (Darsalia et al. 2014). Ex-4 
has been shown to provide protective effects against acute brain injury after stroke and 
hypoxic/ischemic encephalopathy (HIE) (Chen et al. 2016). The precise mechanisms by 
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which this neuroprotection occurs are unclear thus may be studied using the clonal 
TFAR-HEK293T cell line panel model. Further work may also include transduction of a 
range of cell types with the TFAR construct, for example neural progenitor cells (NPCs) 
may be transduced with the TFAR constructs and used to measure fluctuation of TFs 
during neural differentiation.  
7.0 Appendix 
 A.                                                        B.                                                                   
Figure 37. Representation of VLuc Gene construct consisting of A.) A Constitutively active control 
promoter, B.) The gene for secreted VLuc.  
 
TFAR Clone Selected 
NFκB G2 
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TCF/LEF (Wnt) D12 
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NRF2 A9 
TFEB G6 
Figure 38. Selected clonal populations transduced with the TFAR construct of choice.   
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7.1 Validation of cell screening model with TNF-α (GFP images) 
 
 
Figure 39. Treatment of Clonal NFκB (G2) with TNF-α. Ai). Phase-contrast images of NFκB transduced 
clone G2 treated with the vehicle control. Aii). Correlating GFP images. Bi.) ). Phase-contrast images of 
NFκB transduced clone G2 treated with TNF-α (10ng/ml, 16hrs). Bii). Correlating GFP images. GFP 
images displayed upregulated expression of NFκB on addition of TNF-α The NFκB TFAR was used as a 
positive control. All images were taken at 20X magnification using Leica Live Cell Imaging System. Scale 
bar 50μm. 
 
 
 
Figure 40. Treatment of Clonal AP-1 (F4) with TNF-α.  Ai). Phase-contrast images of AP-1 transduced 
clone A9 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
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AP-1 transduced clone G2 treated with TNF-α (10ng/ml, 16hrs).  Bii). Correlating GFP images. GFP 
images did not display upregulated expression of AP-1 on addition of TNF-α. All images were taken at 
20X magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
 
 
 
Figure 41. Treatment of Clonal HIF (B5) with TNF-α. Ai). Phase-contrast images of HIF transduced clone 
B5 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of HIF 
transduced clone B5 treated with TNF-α (10ng/ml, 16hrs).  Bii). Correlating GFP images. GFP images did 
not display clear upregulated expression of HIF on addition of TNF-α. All images were taken at 20X 
magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
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Figure 42. Treatment of Clonal TFEB (G6) with TNF-α. Ai). Phase-contrast images of TFEB transduced 
clone G6 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
TFEB transduced clone G6 treated with TNF-α (10ng/ml, 16hrs).  Bii). Correlating GFP images. GFP 
images did not display clear upregulated expression of TFEB on addition of TNF-α. All images were 
taken at 20X magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
 
 
 
 
Figure 43. Treatment of Clonal STAT3 (C7i) with TNF-α. Ai). Phase-contrast images of STAT3 transduced 
clone C7i treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
STAT3 transduced clone C7i treated with TNF-α (10ng/ml, 16hrs). Bii). Correlating GFP images. GFP 
images did not display clear upregulated expression of TFEB on addition of TNF-α. All images were 
taken at 20X magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
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Figure 44. Treatment of Clonal TCF/LEF (D12) with TNF-α. Ai). Phase-contrast images of TCF/LEF (Wnt 
signalling) transduced clone D12 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  
Phase-contrast images of TCF/LEF (Wnt signalling) TFAR transduced clone D12 treated with TNF-α 
(10ng/ml, 16hrs). Bii). Correlating GFP images. GFP images did not display clear upregulated expression 
of TCF/LEF (wnt signalling) on addition of TNF-α. All images were taken at 20X magnification using Leica 
Live Cell Imaging System. Scale bar 50μm. 
 
 
 
Figure 45. Treatment of Clonal NRF2 (A9) with TNF-α. Ai). Phase-contrast images of NRF2 TFAR transduced clone 
A9 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of NRF2 clone A9 
treated with TNF-α (10ng/ml, 16hrs). Bii). Correlating GFP images. GFP images did not display clear upregulated 
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expression of NRF2 on addition of TNF-α. All images were taken at 20X magnification using Leica Live Cell Imaging 
System. Scale bar 50μm. 
 
 
 
 
 
7.2 Model for drug testing: LiCl2 (GFP images)   
 
Figure 46. Treatment of Clonal TCF/LEF (D12) with LiCl2. Ai). Phase-contrast images of TCF/LEF (Wnt 
signalling) transduced clone D12 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-
contrast images of TCF/LEF (Wnt signalling) TFAR transduced clone D12 treated with 50mM LiCl2 (48 hours). 
Bii). Correlating GFP images. GFP images displayed clear upregulated expression of TCF/LEF (Wnt signalling) 
on addition of LiCl2. All images were taken at 20X magnification using Leica Live Cell Imaging System. Scale 
bar 50μm. 
 
 
76 | P a g e  
 
 
Figure 47. Treatment of Clonal HIF (B5) with LiCl2. Ai). Phase-contrast images of HIF transduced clone 
B5 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of HIF TFAR 
transduced clone B5 treated with 50mM LiCl2 (48 hours). Bii). Correlating GFP images. GFP images 
displayed clear upregulated expression of HIF on addition of LiCl2. All images were taken at 20X 
magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
 
 
 
 
 
 
 
Figure 48. Treatment of Clonal STAT3 (C7i) with LiCl2. Ai). Phase-contrast images of STAT3 transduced 
clone C7i treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
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STAT3 TFAR transduced clone C7i treated with 50mM LiCl2 (48 hours). Bii). Correlating GFP images. GFP 
images displayed clear upregulated expression of STAT3 on addition of LiCl2. All images were taken at 
20X magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
 
 
 
Figure 49. Treatment of Clonal NRF2 (A9) with LiCl2. Ai). Phase-contrast images of NRF2 transduced 
clone A9 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
NRF2 TFAR transduced clone A9 treated with 50mM LiCl2 (48 hours). Bii). Correlating GFP images. GFP 
images displayed clear upregulated expression of NRF2 on addition of LiCl2. All images were taken at 
20X magnification using Leica Live Cell Imaging System. Scale bar 50μm.  
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Figure 50. Treatment of Clonal AP-1 (F4) with LiCl2. Ai). Phase-contrast images of AP-1 transduced 
clone F4 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
AP-1 TFAR transduced clone F4 treated with 50mM LiCl2 (48 hours). Bii). Correlating GFP images. GFP 
images displayed clear upregulated expression of AP-1 on addition of LiCl2. All images were taken at 
20X magnification using Leica Live Cell Imaging System. Scale bar 50μm.  
 
 
 
Figure 51. Treatment of Clonal TFEB (G6) with LiCl2. Ai). Phase-contrast images of TFEB transduced 
clone G6 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
TFEB TFAR transduced clone G6 treated with 50mM LiCl2 (48 hours). Bii). Correlating GFP images. GFP 
images displayed clear upregulated expression of TFEB on addition of LiCl2. All images were taken at 
20X magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
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Figure 52. Treatment of Clonal NFκB (G2) with LiCl2. Ai). Phase-contrast images of NFκB transduced 
clone G2 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
NFκB TFAR transduced clone G2 treated with 50mM LiCl2 (48 hours). Bii). Correlating GFP images. GFP 
images displayed clear upregulated expression of NFκB on addition of LiCl2. All images were taken at 
20X magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
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7.3 Model for drug testing: PMA (GFP images) 
 
Figure 53. Treatment of Clonal AP-1 (F4) with PMA. Ai). Phase-contrast images of AP-1 transduced 
clone F4 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
AP-1 TFAR transduced clone F4 treated with 10ng/ml PMA (21 hrs). Bii). Correlating GFP images. GFP 
images displayed clear upregulated expression of AP-1 on addition of PMA. All images were taken at 
20X magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
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Figure 54. Treatment of Clonal TFEB (G6) with PMA. Ai). Phase-contrast images of TFEB transduced 
clone G6 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
TFEB TFAR transduced clone G6 treated with 10ng/ml PMA (21 hrs). Bii). Correlating GFP images. GFP 
images displayed upregulated expression of TFEB on addition of PMA. All images were taken at 20X 
magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
 
 
 
Figure 55. Treatment of Clonal TCF/LEF (Wnt signalling) (D12) with PMA. Ai). Phase-contrast images 
of TCF/LEF transduced clone D12 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  
Phase-contrast images of TCF/LEF TFAR transduced clone D12 treated with 10ng/ml PMA (21 hrs). Bii). 
Correlating GFP images. GFP images did not display modulation of TCF/LEF (Wnt signalling) on addition 
of PMA. All images were taken at 20X magnification using Leica Live Cell Imaging System. Scale bar 
50μm. 
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Figure 56. Treatment of Clonal STAT3 (C7i) with PMA. Ai). Phase-contrast images of STAT3 transduced 
clone C7i treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
STAT3 TFAR transduced clone C7i treated with 10ng/ml PMA (21 hrs). Bii). Correlating GFP images. GFP 
images displayed upregulation of STAT3 on addition of PMA. All images were taken at 20X 
magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
 
 
Figure 57. Treatment of Clonal HIF (B5) with PMA. Ai). Phase-contrast images of HIF transduced 
clone B5 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images 
of HIF TFAR transduced clone B5 treated with 10ng/ml PMA (21 hrs). Bii). Correlating GFP images. 
GFP images displayed upregulation of HIF on addition of PMA. All images were taken at 20X 
magnification using Leica Live Cell Imaging System. Scale bar 50μm. 
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Figure 58. Treatment of Clonal NFκB (G2) with PMA. Ai). Phase-contrast images of NFκB transduced 
clone G2 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
NFκB TFAR transduced clone G2 treated with 10ng/ml PMA (21 hrs). Bii). Correlating GFP images. GFP 
images displayed upregulation of NFκB on addition of PMA. All images were taken at 20X magnification 
using Leica Live Cell Imaging System. Scale bar 50μm. 
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Figure 59. Treatment of Clonal NRF2 (A9) with PMA. Ai). Phase-contrast images of NRF2 transduced 
clone A9 treated with the vehicle control. Aii). Correlating GFP images. Bi.)  Phase-contrast images of 
NRF2 TFAR transduced clone A9 treated with 10ng/ml PMA (21 hrs). Bii). Correlating GFP images. GFP 
images displayed upregulation of NRF2 on addition of PMA. All images were taken at 20X magnification 
using Leica Live Cell Imaging System. Scale bar 50μm. 
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